A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Laskowitz
Daniel T
DT
Kolls
Brad J
BJ
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4 / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D004305:Dose-Response Relationship, Drug; D006801:Humans
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4; C545458:bapineuzumab